[{"id":"9f8d313e-74c9-44df-85b7-d0e225eab089","acronym":"KEYSTEP-008","url":"https://clinicaltrials.gov/study/NCT04895722","created_at":"2021-05-20T11:54:07.770Z","updated_at":"2024-07-02T16:34:59.923Z","phase":"Phase 2","brief_title":"Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)","source_id_and_acronym":"NCT04895722 - KEYSTEP-008","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR • RAS wild-type","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-4830 • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A) • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 06/25/2021","start_date":" 06/25/2021","primary_txt":" Primary completion: 10/20/2025","primary_completion_date":" 10/20/2025","study_txt":" Completion: 11/18/2025","study_completion_date":" 11/18/2025","last_update_posted":"2024-05-30"},{"id":"40e9c584-14da-4391-b55e-d2b5af41ff2b","acronym":"MK-1308-001","url":"https://clinicaltrials.gov/study/NCT03179436","created_at":"2021-01-17T17:28:19.740Z","updated_at":"2024-07-02T16:35:09.610Z","phase":"Phase 1/2","brief_title":"Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)","source_id_and_acronym":"NCT03179436 - MK-1308-001","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • BRAF • ALK • CTLA4","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • ALK translocation","tags":["EGFR • BRAF • ALK • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • quavonlimab (MK-1308) • quavonlimab/pembrolizumab (MK-1308A)"],"overall_status":"Completed","enrollment":" Enrollment 413","initiation":"Initiation: 07/02/2017","start_date":" 07/02/2017","primary_txt":" Primary completion: 04/08/2024","primary_completion_date":" 04/08/2024","study_txt":" Completion: 04/08/2024","study_completion_date":" 04/08/2024","last_update_posted":"2024-04-16"}]